0 XP   0   0   0

Neurobo Pharmaceuticals Inc










Financial Health of Neurobo Pharmaceuticals Inc




Comparing to competitors in the Biotechnology industry




  Industry Rankings  


Neurobo Pharmaceuticals Inc
Buy, Hold or Sell?

Should you buy, hold or sell Neurobo Pharmaceuticals Inc?

I guess you are interested in Neurobo Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Neurobo Pharmaceuticals Inc

Let's start. I'm going to help you getting a better view of Neurobo Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Neurobo Pharmaceuticals Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Neurobo Pharmaceuticals Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Neurobo Pharmaceuticals Inc. The closing price on 2022-12-07 was $1.38 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Neurobo Pharmaceuticals Inc Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Neurobo Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Neurobo Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Neurobo Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--223.6%+223.6%
TTM--281.7%+281.7%
YOY--344.8%+344.8%
5Y--450.1%+450.1%
10Y--541.0%+541.0%
1.1.2. Return on Assets

Shows how efficient Neurobo Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Neurobo Pharmaceuticals Inc to the Biotechnology industry mean.
  • -32.8% Return on Assets means that Neurobo Pharmaceuticals Inc generated $-0.33 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is -32.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -47.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-32.8%TTM-47.0%+14.2%
TTM-47.0%YOY-151.0%+104.0%
TTM-47.0%5Y-69.2%+22.2%
5Y-69.2%10Y-63.0%-6.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-32.8%-9.9%-22.9%
TTM-47.0%-8.9%-38.1%
YOY-151.0%-9.3%-141.7%
5Y-69.2%-11.7%-57.5%
10Y-63.0%-12.7%-50.3%
1.1.3. Return on Equity

Shows how efficient Neurobo Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Neurobo Pharmaceuticals Inc to the Biotechnology industry mean.
  • -37.4% Return on Equity means Neurobo Pharmaceuticals Inc generated $-0.37 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is -37.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -55.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-37.4%TTM-55.7%+18.3%
TTM-55.7%YOY-224.4%+168.7%
TTM-55.7%5Y-98.3%+42.6%
5Y-98.3%10Y-77.9%-20.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-37.4%-12.0%-25.4%
TTM-55.7%-11.5%-44.2%
YOY-224.4%-10.8%-213.6%
5Y-98.3%-14.2%-84.1%
10Y-77.9%-15.2%-62.7%

1.2. Operating Efficiency of Neurobo Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Neurobo Pharmaceuticals Inc is operating .

  • Measures how much profit Neurobo Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Neurobo Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.3%+207.3%
TTM--271.0%+271.0%
YOY--325.9%+325.9%
5Y--454.0%+454.0%
10Y--537.1%+537.1%
1.2.2. Operating Ratio

Measures how efficient Neurobo Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.871-2.871
TTM-3.504-3.504
YOY-3.604-3.604
5Y-5.132-5.132
10Y-6.371-6.371

1.3. Liquidity of Neurobo Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Neurobo Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 8.07 means the company has $8.07 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is 8.068. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.187. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.068TTM7.187+0.881
TTM7.187YOY4.550+2.638
TTM7.1875Y4.503+2.685
5Y4.50310Y4.575-0.072
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.0685.117+2.951
TTM7.1875.755+1.432
YOY4.5505.854-1.304
5Y4.5036.511-2.008
10Y4.5756.222-1.647
1.3.2. Quick Ratio

Measures if Neurobo Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Neurobo Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 7.08 means the company can pay off $7.08 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is 7.085. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.520. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.085TTM6.520+0.565
TTM6.520YOY4.231+2.290
TTM6.5205Y4.207+2.313
5Y4.20710Y4.326-0.119
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0854.284+2.801
TTM6.5204.664+1.856
YOY4.2314.787-0.556
5Y4.2075.218-1.011
10Y4.3265.182-0.856

1.4. Solvency of Neurobo Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Neurobo Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Neurobo Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that Neurobo Pharmaceuticals Inc assets are financed with 12.4% credit (debt) and the remaining percentage (100% - 12.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is 0.124. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.153. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.124TTM0.153-0.029
TTM0.153YOY0.272-0.119
TTM0.1535Y0.407-0.254
5Y0.40710Y0.638-0.231
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1240.278-0.154
TTM0.1530.277-0.124
YOY0.2720.306-0.034
5Y0.4070.367+0.040
10Y0.6380.403+0.235
1.4.2. Debt to Equity Ratio

Measures if Neurobo Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Neurobo Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 14.1% means that company has $0.14 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is 0.141. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.185. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.141TTM0.185-0.043
TTM0.185YOY0.391-0.206
TTM0.1855Y0.727-0.542
5Y0.72710Y0.566+0.161
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1410.315-0.174
TTM0.1850.317-0.132
YOY0.3910.319+0.072
5Y0.7270.403+0.324
10Y0.5660.462+0.104

2. Market Valuation of Neurobo Pharmaceuticals Inc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Neurobo Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Neurobo Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -0.13 means the investor is paying $-0.13 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Neurobo Pharmaceuticals Inc:

  • The EOD is -0.371. Company is losing money. -2
  • The MRQ is -0.129. Company is losing money. -2
  • The TTM is -0.400. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-0.371MRQ-0.129-0.242
MRQ-0.129TTM-0.400+0.271
TTM-0.400YOY-19.030+18.630
TTM-0.4005Y-7.258+6.858
5Y-7.25810Y-5.591-1.667
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.371-8.986+8.615
MRQ-0.129-9.792+9.663
TTM-0.400-16.243+15.843
YOY-19.030-20.876+1.846
5Y-7.258-16.665+9.407
10Y-5.591-14.732+9.141
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Neurobo Pharmaceuticals Inc.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is 0.996. Seems overpriced? -1
  • The TTM is 0.624. Good. +1
Trends
Current periodCompared to+/- 
MRQ0.996TTM0.624+0.372
TTM0.624YOY3.277-2.653
TTM0.6245Y-0.077+0.701
5Y-0.07710Y1.800-1.877
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.996-0.032+1.028
TTM0.6240.004+0.620
YOY3.2770.016+3.261
5Y-0.0770.006-0.083
10Y1.8000.003+1.797

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Neurobo Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.05 means the investor is paying $0.05 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Neurobo Pharmaceuticals Inc:

  • The EOD is 0.139. Very good. +2
  • The MRQ is 0.048. Very good. +2
  • The TTM is 0.182. Very good. +2
Trends
Current periodCompared to+/- 
EOD0.139MRQ0.048+0.091
MRQ0.048TTM0.182-0.134
TTM0.182YOY10.517-10.335
TTM0.1825Y3.091-2.909
5Y3.09110Y2.353+0.738
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.1391.835-1.696
MRQ0.0482.006-1.958
TTM0.1822.774-2.592
YOY10.5173.453+7.064
5Y3.0912.713+0.378
10Y2.3532.402-0.049
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Neurobo Pharmaceuticals Inc.

3.1. Institutions holding Neurobo Pharmaceuticals Inc

Institutions are holding 5.934% of the shares of Neurobo Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-06-30Vanguard Group Inc1.8296049399500
2022-06-30Murchinson Ltd.0.76020.018820525600
2022-06-30Susquehanna International Group, LLP0.40201085411085410
2022-06-30Sabby Management LLC0.34580.030693376-279735-74.9737
2022-06-30Geode Capital Management, LLC0.241806529000
2022-06-30Renaissance Technologies Corp0.2198059356593560
2022-06-30Mount Yale Investment Advisors, LLC0.21270.00355742500
2022-06-30TWO SIGMA SECURITIES, LLC0.150.00074049630292296.864
2022-06-30Millennium Management LLC0.0891024056240560
2022-06-30Northern Trust Corp0.063501715500
2022-06-30State Street Corporation0.061301655800
2022-06-30Tower Research Capital LLC0.05450.00021472013174852.1345
2022-06-30UBS Group AG0.011403066-8187-72.7539
2022-06-30CapTrust Financial Advisors0.01130304400
2022-06-30Group One Trading, LP0.0016043800
2022-06-30Wells Fargo & Co0.0013035661.7143
2022-06-30Bank of America Corp0.0009024000
2022-06-30Royal Bank of Canada0.0006016600
2022-06-30Truvestments Capital LLC0.0001029290
2022-06-30JANE STREET GROUP, LLC000-12977-100
Total 4.45750.05381203563-65445-5.4%

3.2. Funds holding Neurobo Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-09-30Vanguard Instl Ttl Stck Mkt Idx Tr1.058709409-4237-31.0494
2022-10-31Vanguard Total Stock Mkt Idx Inv1.05870940900
2022-09-30DFA US Small Cap I0.32020.0003284628460
2022-10-31Vanguard Extended Market Index Investor0.22320198400
2022-09-30Fidelity® Extended Market Index0.12520.0001111300
2022-09-30Fidelity® NASDAQ Composite Index®0.1030.0001915-1-0.1092
2022-10-31Dimensional US Small Cap ETF0.08870.000178800
2022-09-30DFA US Targeted Value I0.0820.00017297290
2022-09-30SSgA U.S. Extended Market Index Class I0.04010.0002356-1-0.2801
2022-09-30State St US Extended Mkt Indx NL Cl C0.04010.0002356-1-0.2801
2022-10-31Dimensional US Targeted Value ETF0.0294026100
2022-09-30Vanguard U.S. Eq Idx £ Acc0.020701841782966.6667
2022-09-30NT Quality SCC US Fund - L0.01950.000917300
2022-09-30NT Quality Small Cap Core0.01950.000917300
2022-09-30Northern Trust Extended Eq Market Idx0.0190.000116900
2022-09-30NT Ext Equity Mkt Idx Fd - L0.0190.000116900
2022-09-30Fidelity® Series Total Market Index0.01370122-1-0.813
2022-09-30SSgA U.S. Total Market Index Strategy0.0124011000
2022-09-30NT Ext Equity Mkt Idx Fd - NL0.001801600
2022-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.001501300
Total 3.29640.003129295-488-1.7%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Neurobo Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---3.4832.378-246%-0.082-98%-0.501-86%0.368-1046%
Book Value Growth---0.350-0.135-61%-0.096-73%-0.382+9%0.472-174%
Book Value Per Share--9.93911.669-15%0.451+2106%7.191+38%7.899+26%
Book Value Per Share Growth---0.3500.236-248%-0.187-47%-0.586+67%0.315-211%
Current Ratio--8.0687.187+12%4.550+77%4.503+79%4.575+76%
Debt To Asset Ratio--0.1240.153-19%0.272-54%0.407-70%0.638-81%
Debt To Equity Ratio--0.1410.185-24%0.391-64%0.727-81%0.566-75%
Dividend Per Share----0%-0%-0%-0%
Eps---3.717-3.999+8%-0.389-90%-3.875+4%-4.335+17%
Eps Growth---0.130-0.184+42%0.755-117%1.209-111%0.948-114%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.139+65%0.0480.182-74%10.517-100%3.091-98%2.353-98%
Pe Ratio-0.371-188%-0.129-0.400+210%-19.030+14641%-7.258+5522%-5.591+4231%
Peg Ratio--0.9960.624+60%3.277-70%-0.077+108%1.800-45%
Price Per Share1.380+65%0.4801.580-70%4.650-90%4.749-90%5.076-91%
Price To Total Gains Ratio-0.396-188%-0.1380.066-308%-226.445+164260%-45.839+33171%-38.214+27637%
Profit Growth---12.95888.649-115%136.313-110%60.189-122%43.631-130%
Quick Ratio--7.0856.520+9%4.231+67%4.207+68%4.326+64%
Return On Assets---0.328-0.470+43%-1.510+361%-0.692+111%-0.630+92%
Return On Equity---0.374-0.557+49%-2.244+500%-0.983+163%-0.779+108%
Total Gains Per Share---3.4832.378-246%-0.082-98%-0.501-86%0.368-1046%
Total Gains Per Share Growth---0.137-0.747+444%1.313-110%-0.111-19%-0.292+113%
Usd Book Value--8833000.00010370750.000-15%8315000.000+6%9044000.000-2%8985111.111-2%
Usd Book Value Change Per Share---3.4832.378-246%-0.082-98%-0.501-86%0.368-1046%
Usd Book Value Per Share--9.93911.669-15%0.451+2106%7.191+38%7.899+26%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---3.717-3.999+8%-0.389-90%-3.875+4%-4.335+17%
Usd Price Per Share1.380+65%0.4801.580-70%4.650-90%4.749-90%5.076-91%
Usd Profit---3303000.000-6230750.000+89%-16582750.000+402%-7936700.000+140%-7181037.037+117%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---3.4832.378-246%-0.082-98%-0.501-86%0.368-1046%
 EOD+2 -3MRQTTM+13 -14YOY+14 -135Y+16 -1110Y+16 -11

4.2. Fundamental Score

Let's check the fundamental score of Neurobo Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.371
Price to Book Ratio (EOD)Between0-10.139
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than17.085
Current Ratio (MRQ)Greater than18.068
Debt to Asset Ratio (MRQ)Less than10.124
Debt to Equity Ratio (MRQ)Less than10.141
Return on Equity (MRQ)Greater than0.15-0.374
Return on Assets (MRQ)Greater than0.05-0.328
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Neurobo Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.430
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets10,082
Total Liabilities1,249
Total Stockholder Equity8,833
 As reported
Total Liabilities 1,249
Total Stockholder Equity+ 8,833
Total Assets = 10,082

Assets

Total Assets10,082
Total Current Assets10,077
Long-term Assets10,077
Total Current Assets
Cash And Cash Equivalents 8,849
Other Current Assets 1,228
Total Current Assets  (as reported)10,077
Total Current Assets  (calculated)10,077
+/-0
Long-term Assets
Property Plant Equipment 5
Long-term Assets  (as reported)5
Long-term Assets  (calculated)5
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,249
Long-term Liabilities0
Total Stockholder Equity8,833
Total Current Liabilities
Accounts payable 664
Other Current Liabilities 585
Total Current Liabilities  (as reported)1,249
Total Current Liabilities  (calculated)1,249
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock27
Retained Earnings -88,006
Other Stockholders Equity 96,812
Total Stockholder Equity (as reported)8,833
Total Stockholder Equity (calculated)8,833
+/-0
Other
Capital Stock27
Cash and Short Term Investments 8,849
Common Stock Shares Outstanding 889
Liabilities and Stockholders Equity 10,082
Net Debt -8,849
Net Invested Capital 8,833
Net Tangible Assets 8,833
Net Working Capital 8,828



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
> Total Assets 
0
0
0
4,500
1,658
6,726
28,924
24,754
29,842
23,004
26,211
19,017
34,837
28,806
24,870
19,694
6,158
4,014
2,048
14,468
11,535
15,552
13,198
10,968
10,838
10,719
8,077
16,799
13,461
10,082
10,08213,46116,7998,07710,71910,83810,96813,19815,55211,53514,4682,0484,0146,15819,69424,87028,80634,83719,01726,21123,00429,84224,75428,9246,7261,6584,500000
   > Total Current Assets 
0
0
0
3,643
1,653
6,718
28,916
24,746
29,834
22,974
26,203
19,009
34,829
28,798
24,862
19,686
6,106
3,988
2,048
14,118
11,211
15,243
12,898
10,683
10,683
10,468
7,844
16,584
13,264
10,077
10,07713,26416,5847,84410,46810,68310,68312,89815,24311,21114,1182,0483,9886,10619,68624,86228,79834,82919,00926,20322,97429,83424,74628,9166,7181,6533,643000
       Cash And Cash Equivalents 
0
0
0
3,620
1,629
4,826
28,369
24,033
29,282
22,491
25,340
18,473
34,461
28,039
23,806
18,954
5,510
3,643
1,855
13,908
9,799
14,298
12,353
10,089
10,089
9,513
6,984
16,387
11,557
8,849
8,84911,55716,3876,9849,51310,08910,08912,35314,2989,79913,9081,8553,6435,51018,95423,80628,03934,46118,47325,34022,49129,28224,03328,3694,8261,6293,620000
       Other Current Assets 
0
0
0
23
24
1,892
547
713
552
483
863
536
368
759
1,056
732
596
345
193
210
1,412
945
545
594
594
955
860
197
1,707
1,228
1,2281,7071978609555945945459451,4122101933455967321,0567593685368634835527135471,8922423000
   > Long-term Assets 
0
0
0
857
5
8
8
8
8
30
8
8
8
8
8
8
52
26
0
350
324
309
300
285
155
251
233
215
197
5
5197215233251155285300309324350026528888883088885857000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
3
44
18
237
350
324
277
267
155
155
251
233
215
197
5
519721523325115515526727732435023718443300000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
9
8
8
32
0
0
32
33
0
130
0
0
0
0
0
00000130033320032889900000000000000
> Total Liabilities 
0
0
0
16,880
2,252
22,681
1,936
4,122
4,545
5,274
16,262
15,076
14,020
13,758
14,017
11,920
1,712
2,050
3,073
2,176
3,795
3,214
3,692
3,765
3,765
1,241
1,952
2,202
1,533
1,249
1,2491,5332,2021,9521,2413,7653,7653,6923,2143,7952,1763,0732,0501,71211,92014,01713,75814,02015,07616,2625,2744,5454,1221,93622,6812,25216,880000
   > Total Current Liabilities 
0
0
0
8,927
2,252
14,429
1,936
4,121
4,543
5,272
6,295
6,390
6,257
6,215
7,617
11,919
1,712
2,050
3,073
2,082
3,706
3,132
3,615
3,695
3,695
1,183
1,901
2,157
1,496
1,249
1,2491,4962,1571,9011,1833,6953,6953,6153,1323,7062,0823,0732,0501,71211,9197,6176,2156,2576,3906,2955,2724,5434,1211,93614,4292,2528,927000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
1,355
2,355
2,652
3,681
9,437
9,437
0
0
0
0
0
0
0
24
25
26
26
27
0
0272626252400000009,4379,4373,6812,6522,3551,35500000000000
       Accounts payable 
0
0
0
531
224
642
1,257
2,008
3,541
3,464
4,332
4,025
2,848
2,569
2,351
2,044
1,234
1,668
2,677
638
1,273
1,683
1,101
3,671
2,575
347
953
830
776
664
6647768309533472,5753,6711,1011,6831,2736382,6771,6681,2342,0442,3512,5692,8484,0254,3323,4643,5412,0081,257642224531000
       Other Current Liabilities 
0
0
0
8,396
2,028
13,787
679
2,113
1,002
1,808
1,963
1,010
1,054
994
1,585
438
478
382
396
1,444
2,433
1,449
2,514
94
1,120
811
922
1,301
693
585
5856931,3019228111,120942,5141,4492,4331,4443963824784381,5859941,0541,0101,9631,8081,0022,11367913,7872,0288,396000
   > Long-term Liabilities 
0
0
0
7,953
0
8,252
0
1
2
2
9,967
8,686
7,763
7,543
6,400
1
1
0
0
94
89
82
77
70
70
58
51
45
37
0
03745515870707782899400116,4007,5437,7638,6869,96722108,25207,953000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,398
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000006,39800000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23
23
35
35
42
0
0
0
0
0
0
0
0
0
0
0
00000000000423535232300000000000000
> Total Stockholder Equity
0
0
0
-12,380
-594
-15,955
26,988
20,632
25,297
17,730
9,949
3,941
20,817
15,048
10,853
7,774
4,446
1,964
-1,025
12,292
7,740
12,338
9,506
7,203
7,203
9,478
6,125
14,597
11,928
8,833
8,83311,92814,5976,1259,4787,2037,2039,50612,3387,74012,292-1,0251,9644,4467,77410,85315,04820,8173,9419,94917,73025,29720,63226,988-15,955-594-12,380000
   Common Stock
0
0
0
12
12
12
17
17
18
18
18
18
22
22
22
22
22
22
23
16
16
17
17
20
20
22
22
27
27
27
272727222220201717161623222222222222181818181717121212000
   Retained Earnings Total Equity0000-73,789-69,868-66,54400000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-17
-28
-40
-51
14
14
3
4
4
3
0
034431414-51-40-28-170000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
91,286
91,863
92,336
92,774
93,214
49,130
49,342
0
0
73,713
82,990
83,242
0
0
0
0
000083,24282,99073,7130049,34249,13093,21492,77492,33691,86391,28600000000000000
   Treasury Stock000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
13,929
0
46,816
47,674
59,834
62,769
63,659
64,397
88,493
89,402
91,286
91,863
92,336
92,774
93,214
49,159
49,348
56,341
56,574
14
7,155
83,242
83,349
96,394
96,601
96,812
96,81296,60196,39483,34983,2427,1551456,57456,34149,34849,15993,21492,77492,33691,86391,28689,40288,49364,39763,65962,76959,83447,67446,816013,9290000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-15,298
Operating Income-15,298-15,298
 
Operating Expense (+$)
Research Development6,546
Selling General Administrative8,752
Selling And Marketing Expenses-
Operating Expense15,29815,298
 
Net Interest Income (+$)
Interest Income14
Interest Expense-0
Net Interest Income1414
 
Pretax Income (+$)
Operating Income-15,298
Net Interest Income14
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-15,284-15,312
EBIT - interestExpense = -15,298
-15,284
-15,284
Interest Expense0
Earnings Before Interest and Taxes (ebit)-15,298-15,284
Earnings Before Interest and Taxes (ebitda)-15,298
 
After tax Income (+$)
Income Before Tax-15,284
Tax Provision-0
Net Income From Continuing Ops-15,284-15,284
Net Income-15,284
Net Income Applicable To Common Shares-15,284
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net14-14
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
MAID.CC
now

I found you a STOCH Bullish Reversal Divergence on the daily chart of MAID.CC.

MAID.CC Daily Candlestick Chart
LIKE.CC
5 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of LIKE.CC.

LIKE.CC Daily Candlestick Chart
LBK.CC
6 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of LBK.CC.

LBK.CC Daily Candlestick Chart
JOINT.CC
11 minutes ago

I found you a Death Cross on the daily chart of JOINT.CC.

JOINT.CC Daily Candlestick Chart
ION.CC
14 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ION.CC.

ION.CC Daily Candlestick Chart
RV.V
20 minutes ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of RV.V.

RV.V Daily Candlestick Chart
SCL.TO
22 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of SCL.TO.

SCL.TO Daily Candlestick Chart
PRU.TO
27 minutes ago

I found you a MACD Bullish Hidden Divergence on the daily chart of PRU.TO.

PRU.TO Daily Candlestick Chart
XSQ.TO
33 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XSQ.TO.

XSQ.TO Daily Candlestick Chart
NA.TO
35 minutes ago

I found you a Golden Cross on the daily chart of NA.TO.

NA.TO Daily Candlestick Chart
MNT.TO
36 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MNT.TO.

MNT.TO Daily Candlestick Chart
MOGO.TO
36 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of MOGO.TO.

MOGO.TO Daily Candlestick Chart
L.TO
41 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of L.TO.

L.TO Daily Candlestick Chart
HZD.TO
44 minutes ago

I found you a Death Cross on the daily chart of HZD.TO.

HZD.TO Daily Candlestick Chart
TLGN.PINK
48 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of TLGN.PINK.

TLGN.PINK Daily Candlestick Chart
GXE.TO
49 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of GXE.TO.

GXE.TO Daily Candlestick Chart
NHK.TO
52 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of NHK.TO.

NHK.TO Daily Candlestick Chart
ZMU.TO
53 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ZMU.TO.

ZMU.TO Daily Candlestick Chart
PNPN.V
56 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of PNPN.V.

PNPN.V Daily Candlestick Chart
TRL.TO
56 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of TRL.TO.

TRL.TO Daily Candlestick Chart
VBNK.TO
58 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VBNK.TO.

VBNK.TO Daily Candlestick Chart
VCB.TO
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VCB.TO.

VCB.TO Daily Candlestick Chart
ZDH.TO
1 hour ago

I found you a Golden Cross on the daily chart of ZDH.TO.

ZDH.TO Daily Candlestick Chart
MUS.TO
1 hour ago

I found you a Golden Cross on the daily chart of MUS.TO.

MUS.TO Daily Candlestick Chart
VRIF.TO
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VRIF.TO.

VRIF.TO Daily Candlestick Chart